RecruitingNCT06651177
Tirzepatide added to buprenorphine for opioid use disorder
About this title
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Read the official source — NCT06651177Medication studyAges 18+United StatesAddiction
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- Jacksonville and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 29, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 310
- Sponsor
- T. John Winhusen, PhD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT06651177
- Official title
Show the full official title
NIDA CTN-0152: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: A Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Jacksonville · Tampa · Chicago
6 more locations
- Cape Girardeau
- Greenville
- Nashville
- Salt Lake City
- Huntington
- Morgantown
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is T. John Winhusen, PhD.
Does this study involve medication?
Yes. The study involves medication, including Tirzepatide.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
